Last reviewed · How we verify
VGN-R09b
At a glance
| Generic name | VGN-R09b |
|---|---|
| Sponsor | Shanghai Vitalgen BioPharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's Disease (PHASE1, PHASE2)
- A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency (PHASE1)
- An Early Clinical Trial to Evaluate VGN-R09b for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency. (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VGN-R09b CI brief — competitive landscape report
- VGN-R09b updates RSS · CI watch RSS
- Shanghai Vitalgen BioPharma Co., Ltd. portfolio CI